Status:
ACTIVE_NOT_RECRUITING
Renal Metabolism in Salt-sensitive Human Blood Pressure
Lead Sponsor:
Medical College of Wisconsin
Conditions:
Hypertension
Eligibility:
All Genders
30-65 years
Phase:
NA
Brief Summary
Salt sensitive hypertension is a significant health problem worldwide and a primary modifiable risk factor for renal, cardiovascular, and cerebrovascular diseases. Yet, the underlying mechanisms remai...
Detailed Description
Seventy subjects will be enrolled and randomized to start either a low sodium diet (1200 mg/day) or high sodium diet (\>4200 mg/day) for two weeks. After completion of two weeks, subjects will be swit...
Eligibility Criteria
Inclusion
- English speaking subjects
- With a spectrum of BPs, ranging from those with Elevated BP through Stage 1 HTN, as defined by the 2017 ACC/AHA HTN guidelines
Exclusion
- Non-English speakers
- BP ≤120/80 \& ≥ 140/90 mmHg
- H/o diabetes, congestive heart failure, cirrhosis of the liver, hypokalemia \& other
- electrolyte disturbances
- H/o kidney disease
- Use of glucocorticoids
- Pregnant or nursing mothers
- Presence of bleeding disorders
- Use of anti-platelet and anticoagulant agents such as clopidogrel, aspirin, dabigatran, rivaroxaban etc
- Daily sodium intake ≥ 6000 mg/day
- Presence of pacemaker or other metallic implants
- Allergy to iodinated contrast
- Allergy to shellfish
- Claustrophobia
Key Trial Info
Start Date :
November 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 30 2030
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT05369416
Start Date
November 1 2021
End Date
January 30 2030
Last Update
November 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical College of Wisconsin /Froedtert Hospital
Milwaukee, Wisconsin, United States, 53226